You are here: Industry Insights > Novartis

News List

Novartis' oral therapy iptacopan shows promise in PNH pharmatimes
June 16, 2021
Novartis has revealed new positive data for its investigational treatment iptacopan as a monotherapy treatment for patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH).
Rafael Holdings Announces Appointments to its Board of Directors firstwordpharma
June 15, 2021
Rafael Holdings, Inc., (NYSE: RFL), today announced the appointment of three senior biopharmaceutical leaders to its Board of Directors: Ameet Mallik, Chief Executive Officer of Rafael Holdings; Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc..
Novartis Announces Iptacopan Met Primary Endpoint in Rare Kidney Disease IgA Nephropathy americanpharmaceuticalreview
June 09, 2021
Novartis announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, oral, targeted factor B inhibitor – reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating ...
Novartis Tislelizumab Meets Primary Endpoint of Overall Survival in Esophageal Cancer americanpharmaceuticalreview
June 08, 2021
Novartis announced results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001).
Novartis’ CAR T therapy Kymriah shows promise in follicular lymphoma pharmatimes
June 04, 2021
Novartis’ CAR T therapy Kymriah has shown promise for the treatment of relapsed or refractory follicular lymphoma – the second most common form of non-Hodgkin lymphoma (NHL).
Novartis reports 'clinically relevant' survival data for Lutathera pharmatimes
June 04, 2021
Novartis has reported findings of a final analysis of data from the Phase III Netter trial, showing that its radioligand therapy Lutathera (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) extended overall survival in patients ...
Novartis Presents Positive Results from JUNIPERA Study Supporting Cosentyx as a Treatment in a JIA Population americanpharmaceuticalreview
June 04, 2021
Novartis, a leader in rheumatology and immuno-dermatology, announced 2-year positive results from the Phase III JUNIPERA study, demonstrating that Cosentyx? (secukinumab) significantly delayed time to flare vs placebo (P<.001) in pediatric patients ...
FDA Approves Novartis Cosentyx for Children with Plaque Psoriasis americanpharmaceuticalreview
June 04, 2021
Novartis, a leader in immuno-dermatology and rheumatology, announced that the FDA has approved Cosentyx? (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic ...
Cosentyx approved to treat plaque psoriasis in paediatric patients pharmatimes
June 03, 2021
The US Food and Drug Administration (FDA) has approved Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx for the treatment of children and adolescents with moderate to severe plaque psoriasis.
Novartis and Molecular Partners commence Covid-19 treatment trial pharmaceutical-technology
May 31, 2021
Novartis and Molecular Partners have commenced Phase II/III EMPATHY clinical trial of a new DARPin therapeutic candidate, ensovibep (MP0420), to treat Covid-19.